Background
Methotrexate (MTX) is the most widely used disease modifying anti-rheumatic drug in juvenile idiopathic arthritis (JIA), inducing long-lasting remission in many patients. It usually takes 6-12 weeks before anti-inflammatory effects are clinically noticed, suggesting modulatory effects on T cells. We examined the effect of MTX on (induced) regulatory T cells (T reg ) in JIA.
Materials and methods
We sampled 11 patients with active poly-articular JIA (poly-JIA) prior to and 3-6 months after initiating MTX. Moreover, 11 poly-JIA patients in remission on MTX were sampled prior to and 3-6 months after withdrawal of MTX. Frequency and characteristics of Foxp3+CD4+T reg and effector T cell subsets were analyzed by flowcytometry. Function of T reg was evaluated in suppression assays. Responses to human heat shock protein 60 (HSP60) were studied in proliferation assays.
Results
MTX-treatment resulted in a decrease of Foxp3+CD4+ T reg (3,7% to 2,8% of CD4+T cells). Suppressive function of T reg was not altered by MTX. Interestingly, stimulation with anti-CD3 resulted in increased proliferation of CD4+CD25-effector T cells after 3 months MTX compared to pre-MTX. Moreover, proliferative responses to human HSP60 increased after MTX-treatment. The quality of the HSP60-response changed with a less pro-inflammatory cytokine profile in supernatants after MTX-treatment. When JIA-patients in remission on MTX-treatment withdrawed MTX, the frequency of T reg increased (3,2 to 3,8% of CD4+ T cells) but their suppressive function remained unchanged.
Conclusion
MTX seems to exert its immune-modulating effects not by affecting Foxp3+ T reg . Instead, we observed changes in effector T cells and HSP60 specific T cells.
from 15 th Paediatric Rheumatology European Society (PreS) Congress London, UK. 14-17 September 2008
